Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine

• Published in: Clinical immunology (Orlando, Fla.) Vol. 230; p. 108818
• Main Authors: García-Grimshaw, Miguel, Michel-Chávez, Anaclara, Vera-Zertuche, Juan Mauricio, Galnares-Olalde, Javier Andrés, Hernández-Vanegas, Laura E., Figueroa-Cucurachi, Melissa, Paredes-Ceballos, Orlando, Reyes-Terán, Gustavo, Carbajal-Sandoval, Guillermo, Ceballos-Liceaga, Santa Elizabeth, Arauz, Antonio, Valdés-Ferrer, Sergio Iván
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2021
• Subjects: Cohort Studies; COVID-19 - prevention & control; COVID-19 vaccine; COVID-19 Vaccines - adverse effects; COVID-19 Vaccines - immunology; Guillain-Barre Syndrome - etiology; Guillain-Barré syndrome; Humans; mRNA vaccines; Retrospective Studies; SARS-CoV-2; Vaccine hesitancy; Vaccine safety; mRNA vaccines; COVID-19 vaccine; Vaccine safety; Vaccine hesitancy; Guillain-Barré syndrome

Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worl...